Clinical Trials on HNSCC

Total 108 results

Groupe Oncologie Radiotherapie Tete et Cou

Completed

Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (TAPIS)

HNSCC

France
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER; Center Eugene Marquis

Active, not recruiting

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN (REWRITe)

HNSCC

France
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER

Active, not recruiting

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)

HNSCC

France
The Netherlands Cancer Institute

Completed

Dose-Effect Relation of Salivary Gland Irradiation

HNSCC

Netherlands
SparX Biotech(Jiangsu) Co., Ltd.

Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303)

Solid Tumor | CRC | HNSCC | RCC

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid Tumors

China
Sichuan Cancer Hospital and Research Institute

Recruiting

MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer

HNSCC

China
National Cancer Institute (NCI)

Recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers | Advanced HNSCC

United States
CJ Bioscience, Inc.

Recruiting

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Melanoma | NSCLC | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | HNSCC

Korea, Republic of
BeiGene

Recruiting

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma

MRI | HNSCC | AI | Radiomic

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC (HNC-SYSU-002)

Oral Cancer | HNSCC | PD-1

China
University of Chicago

Active, not recruiting

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II)

HNSCC | HPV-Related Squamous Cell Carcinoma

United States
Danish Head and Neck Cancer Group

Completed

DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole

HNSCC,Larynx, Pharynx and Oral Cavity

Denmark
University of Arizona
George Washington University

Recruiting

Immune Modulation by Abemaciclib in HNSCC. (AIM Trial)

HNSCC

United States
University of Cincinnati
IsoRay Medical, Inc.

Active, not recruiting

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

HNSCC

United States
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (2007-01)

HNSCC

France
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Kura Oncology, Inc.

Active, not recruiting

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)

HNSCC | HRAS Gene Mutation

United States, Belgium, Spain, United Kingdom, Taiwan, Denmark, Korea, Republic of, Netherlands, Thailand, Germany, Malaysia, Austria, Italy, Greece, Australia, Norway
Presage Biosciences
Bristol-Myers Squibb; Celgene

Terminated

Intratumoral Microdosing of Motolimod in HNSCC

HNSCC

United States
Immutep S.A.S.
Merck Sharp & Dohme LLC

Recruiting

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)

HNSCC

United States, Belgium, Spain, United Kingdom, Denmark, Germany, Australia, Romania, Ukraine
Flamingo Therapeutics NV

Recruiting

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

HNSCC

United States, Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Yonsei University

Active, not recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Larynx | Stage II-IVB Operable HNSCC Oral Cavity | Hypopharynx | Oropharynx

Korea, Republic of
Seoul National University Hospital
Chungnam National University Hospital; Korean Cancer Study Group

Completed

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Head and Neck Neoplasms | HNSCC

Korea, Republic of
University of Colorado, Denver
Cancer League of Colorado

Completed

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

HNSCC

United States
M.D. Anderson Cancer Center

Terminated

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC)

HNSCC

United States
University Health Network, Toronto
Princess Margaret Hospital, Canada

Completed

Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)

Head and Neck Cancer | Metastatic Cancer | Advanced Cancer | HNSCC | Squamous Cell Carcinoma

Canada
Chang Gung Memorial Hospital

Unknown

WGA in Platinum-refractory HNSCC Underwent Nivolumab

HNSCC

Taiwan
Yonsei University

Unknown

Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy

HNSCC

Korea, Republic of
Scorpion Therapeutics, Inc.

Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Breast Cancer | Gynecologic Cancer | HNSCC | Solid Tumors, Adult

United States, Spain
Immutep S.A.S.
Merck Sharp & Dohme LLC

Active, not recruiting

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)

NSCLC | HNSCC

Spain, United States, United Kingdom, Australia, Ukraine
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Sichuan Cancer Hospital and Research Institute

Recruiting

The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma

HNSCC

China
Charite University, Berlin, Germany
Helmholtz-Zentrum Dresden-Rossendorf; Max-Delbrück-Centrum Berlin

Recruiting

Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients (KIVAL-KHT)

HNSCC

Germany
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

HNSCC

China
University of Leipzig

Recruiting

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

HNSCC

Germany
AgonOx, Inc.
Providence St Joseph Health; Phio Pharmaceuticals Corp.

Recruiting

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT)

Melanoma | Gynecologic Cancer | Colorectal Cancer | Lung Cancer | HNSCC | Urogenital Cancer

United States
University Health Network, Toronto
AstraZeneca; NeoGenomics Laboratories

Recruiting

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN)

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Canada
Icahn School of Medicine at Mount Sinai

Withdrawn

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Human Papillomavirus (HPV) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
ImmVira Pharma Co. Ltd

Recruiting

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | NSCLC | Advanced Solid Tumor | HNSCC | Esophagus Cancer | Non-melanoma Skin Cancer

China
Kura Oncology, Inc.

Recruiting

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

HNSCC

United States
Dan Zandberg

Recruiting

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Melanoma | Hepatocellular Carcinoma | NSCLC | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Urothelial Cancer | HNSCC | Microsatellite Instability-High Solid Malignant Tumor

United States
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Groupe Oncologie Radiotherapie Tete et Cou
National Cancer Institute, France

Recruiting

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) (SANTAL)

HNSCC

France
Seoul National University Hospital

Unknown

A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

Head and Neck Neoplasms | HNSCC

Korea, Republic of
Icahn School of Medicine at Mount Sinai

Recruiting

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Navidea Biopharmaceuticals

Terminated

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
ImmVira Pharma Co. Ltd

Recruiting

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Melanoma | Sarcoma | NSCLC | Solid Tumor | HNSCC | Squamous Cell Carcinoma

United States, Australia

Clinical Trials on HNSCC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations